若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

EasySep™小鼠CD4+CD25+调节性T细胞分选试剂盒II

通过免疫磁珠正选分离小鼠CD4+CD25+调节性T细胞
只有 %1
¥11,748.00

产品号 #(选择产品)

产品号 #18783_C

通过免疫磁珠正选分离小鼠CD4+CD25+调节性T细胞

产品优势

  • 快速、易于操作
  • 纯度高达93%
  • 无需分离柱

产品组分包括

  • EasySep™小鼠CD4+CD25+调节性T细胞分离试剂盒II(产品号 #18783)      
    • EasySep™小鼠CD4+ T细胞分选抗体混合物,0.5mL
    • EasySep™ Streptavidin RapidSpheres™ 50001磁珠,1mL          
    • EasySep™小鼠CD25调节性T细胞正选抗体混合物,0.5mL
    • EasySep™PE分选抗体混合物,1mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,1mL
    • EasySep™小鼠FcR阻断剂(产品号 #18731),0.5mL          
  • RoboSep™小鼠CD4+ CD25+调节性T细胞分选试剂盒II(产品号 #18783RF)          
    • EasySep™小鼠CD4+ T细胞分选抗体混合物,0.5mL
    • EasySep™ Streptavidin RapidSpheres™ 50001磁珠,1mL    
    • EasySep™小鼠CD25调节性T细胞正选抗体混合物,0.5mL
    • EasySep™PE分选抗体混合物,1mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,1mL
    • EasySep™小鼠FcR阻断剂(产品号 #18731),0.5mL  
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号 #20125)
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品,请参阅《实验方案与技术文档》

总览

使用EasySep™小鼠CD4+CD25+调节性T细胞分选试剂盒II,通过简单的两步法(首先进行免疫磁珠负选,然后使用正选),即可轻松从小鼠脾细胞或其他单细胞悬液样本中分离出高纯度的小鼠CD4+CD25+调节性T细胞(Tregs)。EasySep™在已发表的研究中被广泛使用了20多年,它结合了单克隆抗体的特异性和无柱磁珠系统的简便性。

在此EasySep™细胞分选过程中,首先使用EasySep™小鼠CD4+ T细胞分选抗体混合物通过负选富集CD4+ T细胞。然后使用EasySep™小鼠CD25调节性T细胞正选抗体混合物从预富集的细胞中正选分离出CD25+细胞。完成磁珠分选后,获得的CD4+CD25+ Tregs即可用于下游应用,例如流式细胞术、培养、DNA/RNA提取。

了解有关EasySep™免疫磁珠技术的工作原理或如何使用RoboSep™进行全自动免疫磁珠细胞分选的更多信息。探索针对您的工作流程进行优化的其他产品,包括培养基、添加物、抗体等。

 

磁极兼容性
• EasySep™磁极(产品号 #18000)
• “The Big Easy” EasySep™磁极(产品号 #18001)
• EasyEights™ EasySep™磁极(产品号 #18103)
• RoboSep™-S(产品号 #21000)
 
分类
细胞分选试剂盒
 
细胞类型
T 细胞,T 细胞,调节性细胞
 
种属
小鼠
 
样本来源
脾脏
 
品牌
EasySep,RoboSep
 
研究领域
免疫
 

实验数据

FACS Histogram Results with EasySep™ Mouse CD4+CD25+ Regulatory T Cell Isolation Kit II

Figure 1. Typical EasySep™ Mouse CD4+CD25+ Regulatory T Cell Isolation Profile

Starting with mouse splenocytes, the regulatory T cell content (CD4+CD25+FOXP3+) of the isolated fraction typically ranges from 70 - 93%. In the above example, the purities of the start and final isolated fractions are 2% and 72%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
产品说明书
Catalog #
18783RF
Lot #
All
Language
中文
Document Type
产品说明书
Catalog #
18783
Lot #
All
Language
中文
Catalog #
18783RF
Lot #
All
Language
English
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 7
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 8
Catalog #
18783RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Catalog #
18783
Lot #
All
Language
English
Document Type
Safety Data Sheet 7
Catalog #
18783
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (11)

常见问题 (7)

Can EasySep™ Streptavidin RapidSpheres™ be used for either positive or negative selection?

Currently, EasySep™ Streptavidin RapidSphere™ kits are only available for negative selection and work by targeting and removing unwanted cells.

How does the separation work?

Streptavidin RapidSphere™ magnetic particles are crosslinked to unwanted cells using biotinylated antibodies. When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a new tube.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ Streptavidin RapidSphere™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Are cells isolated using EasySep™ RapidSphere™ products FACS-compatible?

Yes. Desired cells are unlabeled and ready to use in downstream applications, such as FACS analysis.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

文献 (11)

IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. M. E. Stremska et al. Journal of autoimmunity 2019 may

Abstract

Lupus glomerulonephritis (GN) is an autoimmune disease characterized by immune complex-deposition,complement activation and glomerular inflammation. In lupus-prone NZM2328 mice,the occurrence of lupus GN was accompanied by a decrease in Treg cells and an increase in proinflammatory cytokine-producing T cells. Because IL-33 in addition to IL-2 has been shown to be important for Treg cell proliferation and ST2 (IL-33 receptor) positive Treg cells are more potent in suppressor activity,a hybrid cytokine with active domains of IL-2 and IL-33 was generated to target the ST2+ Treg cells as a therapeutic agent to treat lupus GN. Three mouse models were used: spontaneous and Ad-IFNalpha- accelerated lupus GN in NZM2328 and the lymphoproliferative autoimmune GN in MRL/lpr mice. Daily injections of IL233 for 5 days prevented Ad-IFNalpha-induced lupus GN and induced remission of spontaneous lupus GN. The remission was permanent in that no relapses were detected. The remission was accompanied by persistent elevation of Treg cells in the renal lymph nodes. IL233 is more potent than IL-2 and IL-33 either singly or in combination in the treatment of lupus GN. The results of this study support the thesis that IL233 should be considered as a novel agent for treating lupus GN.
Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells. B. L. Jamison et al. Journal of immunology (Baltimore,Md. : 1950) 2019 jul

Abstract

CD4 T cells play a critical role in promoting the development of autoimmunity in type 1 diabetes. The diabetogenic CD4 T cell clone BDC-2.5,originally isolated from a NOD mouse,has been widely used to study the contribution of autoreactive CD4 T cells and relevant Ags to autoimmune diabetes. Recent work from our laboratory has shown that the Ag for BDC-2.5 T cells is a hybrid insulin peptide (2.5HIP) consisting of an insulin C-peptide fragment fused to a peptide from chromogranin A (ChgA) and that endogenous 2.5HIP-reactive T cells are major contributors to autoimmune pathology in NOD mice. The objective of this study was to determine if poly(lactide-co-glycolide) (PLG) nanoparticles (NPs) loaded with the 2.5HIP Ag (2.5HIP-coupled PLG NPs) can tolerize BDC-2.5 T cells. Infusion of 2.5HIP-coupled PLG NPs was found to prevent diabetes in an adoptive transfer model by impairing the ability of BDC-2.5 T cells to produce proinflammatory cytokines through induction of anergy,leading to an increase in the ratio of Foxp3+ regulatory T cells to IFN-gamma+ effector T cells. To our knowledge,this work is the first to use a hybrid insulin peptide,or any neoepitope,to re-educate diabetogenic T cells and may have significant implications for the development of an Ag-specific therapy for type 1 diabetes patients.
Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells. S. Rajendran et al. Frontiers in oncology 2019

Abstract

Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although,there are effective treatments not every patient responds,necessitating the development of novel therapeutic approaches,especially for relapsed and refractory cases. The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells,the malignant cells in HL. We found that this co-expression is specific for HRS cells. Based on this discovery we developed a bispecific antibody that binds preferentially to the CD30,CD137-double positive HRS cells. The CD30,CD137 bispecific antibody gets internalized into HRS cells opening up the possibility to use it as a carrier for a toxin. This antibody also induces antibody-dependent,cell-mediated cytotoxicity in CD30,CD137-double positive HRS cells. The enhances specificity of the CD30,CD137 bispecific antibody to HRS cells makes it a promising candidate for development as a novel HL treatment.

更多信息

更多信息
物种 小鼠
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 脾脏
标记抗体
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系